Mathematical Modeling of the Acute Inflammatory Response Following Injury

Critical Illness Clinical Trial

Official title:

Mathematical Modeling of the Acute Inflammatory Response Following Injury

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00250523
• Other study ID #: PRO 0801232
• Secondary ID: P50GM053789-09
• Status: Recruiting
• Start date: February 2003
• Est. completion date: July 2022

Study information

• Verified date: March 2021
• Source: National Institute of General Medical Sciences (NIGMS)
• Contact: Stacy D Stull, MS
• Phone: 412-692-4338
• Email: stullsd[@]upmc.edu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this research study is to gather clinical and biologic information from severely injured patients to better understand and characterize the host response to injury and inflammation across several domains. This information may improve outcome prediction, improve clinical treatment of injured patients, and permit the construction of non-biologic computerized models of illness that can be utilized to represent the host response in future research efforts. This study is designed as the calibration of a mathematical model of this response with predictive capabilities.

The central hypothesis governing this study is that adaptive immune elements are crucial to determining the outcome of complex inflammatory scenarios. We propose to test these hypotheses in the following interrelated Specific Aims:

Specific Aim 1: To develop a robust mathematical model describing trauma/hemorrhage-induced inflammation in humans, its pathologic consequences, and possible therapies.

Specific Aim 2: To translate the mathematical model to humans and create software aimed at individualized clinical decision-making.

Specific Aim 3: To determine the prevalence of an IL-1 receptor-associated kinase (IRAK-1) variant haplotype located on the X-chromosome in an injured population, and to characterize differences in the pro-inflammatory response across gender, relative to the IRAK-1 haplotype.

Specific Aim 4: To determine if increased arginase activity previously observed in isolated peripheral blood mononuclear cells of trauma patients is a consequence of the presence of contaminating activated granulocytes or a particular subset of an arginase positive monocyte subset.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 520
• Est. completion date: July 2022
• Est. primary completion date: July 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Trauma patient cohort inclusion criteria:

• Present for treatment of their acute, blunt or penetrating injuries to the University of Pittsburgh Medical Center within 6 hours of injury

• Age greater than or equal to 18 years

• Intact cervical spinal cord

• Are admitted to the Intensive Care Unit

Trauma patient cohort exclusion criteria:

• Anticipated survival < 24 hrs

• Anticipated survival < 28 days due to pre-existing condition

• Traumatic Brain injury (GCS =8 after ICU admission) AND brain CT abnormality within 12 hr of injury

• Inability to obtain consent from the subject or their legally authorized representative.

• Pre-existing immunosuppression

• Transplant recipient

• Chronic high doses of steroids (>20 mg prednisone equivalents/day)

• Significant likelihood of high dose steroids (e.g. spinal cord injury)

• Oncolytic drug(s) therapy within the past 14 days

• Known HIV positive status and CD4 count < 200 cells/mm3

• Admission to the ICU primary for substance withdrawal.

• Inability to obtain 1st blood sample within 24 hours of injury.

Healthy volunteer cohort inclusion:

• Age greater than or equal to 18 years

• Weight > 110 pounds

• no recent illness or infection in the last two weeks

• no recent hospitalization or trauma in the last month

Healthy volunteer cohort exclusion:

• wt < 110 lbs

• infection or illness in the last two weeks

• Hospitalization or trauma in the last month

Related Conditions & MeSH terms

• Critical Illness
• Trauma

Locations

Country	Name	City	State
United States	University of Pittsburgh Medical Center	Pittsburgh	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
National Institute of General Medical Sciences (NIGMS)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Multiple Organ Failure		48 hours